5
Participants
Start Date
July 30, 2019
Primary Completion Date
April 13, 2020
Study Completion Date
April 13, 2020
Poziotinib
The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
Beijing Cancer Hospital, Beijing
Beijing Chest Hospital, Beijing
Beijing Hospital, Beijing
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
Peking Union Medical College Hospital, Beijing
Jilin Cancer Hospital, Changchun
The First Hospital of Jilin University, Changchun
The Third Xiangya Hospital of Central South University, Changsha
Sichuan Cancer Hospital and Institute, Chengdu
West China Hospital of Sichuan University, Chengdu
Fujian Provincial Cancer Hospital, Fuzhou
Guangdong General Hospital, Guangzhou
Guangdong Panyu Central Hospital, Guangzhou
Shi Run Run Shaw Hospital, Zhejiang University, Hangzhou
The First Affiliated Hospital, Zhejiang University, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
The Second Hospital of Anhui Medical University, Hefei
Shanghai Chest Hospital, Shanghai
University of Hong Kong-Shenzhen Hospital, Shenzhen
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Chungbuk National University Hospital, Cheongju-si
National Cancer Center, Gyeonggi-do
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Seoul National University Hospital, Seoul
Lead Sponsor
Hanmi Pharmaceutical Company Limited
INDUSTRY